<DOC>
	<DOCNO>NCT01175356</DOCNO>
	<brief_summary>This clinical trial study induction therapy follow meta-iodobenzylguanidine ( MIBG ) label iodine-131 chemotherapy treat patient newly diagnose high-risk neuroblastoma undergo stem cell transplant , radiation therapy , maintenance therapy isotretinoin . Radioisotope therapy , MIBG label iodine-131 , release radiation kill tumor cell . Drugs use chemotherapy , cisplatin , etoposide , busulfan , melphalan , work different way stop growth tumor cell , either kill cell stop dividing . A peripheral stem cell transplant replace blood-forming cell damage MIBG label iodine-131 chemotherapy .</brief_summary>
	<brief_title>Induction Therapy Including 131 I-MIBG Chemotherapy Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant , Radiation Therapy , Maintenance Therapy With Isotretinoin</brief_title>
	<detailed_description>PRIMARY OBJECTIVE : I . To assess feasibility treat high-risk neuroblastoma patient , age 365 day - 30 year , ) induction block meta-iodobenzylguanidine label iodine-131 ( 131I-MIBG [ iobenguane I 131 ] ) deliver multi-agent chemotherapy , b ) post-induction busulfan/melphalan ( Bu/Mel ) consolidation therapy . SECONDARY OBJECTIVES : I . To assess tolerability treat high-risk neuroblastoma patient , age 365 day - 30 year , ) induction block 131I-MIBG therapy deliver multi-agent chemotherapy , b ) tolerability receive post-induction Bu/Mel consolidation therapy autologous stem-cell rescue ( ASCR ) , local radiation therapy . TERTIARY OBJECTIVES : I . To assess response rate regimen induction chemotherapy 131I-MIBG consolidation regimen Bu/Mel ASCR local radiation therapy . II . To describe relationship tumor norepinephrine transporter ( hNET ) expression radioiodinated MIBG uptake , diagnosis well tumor response . III . To assess relative reliability 123 I-MIBG fludeoxyglucose F-18 ( 18FDG ) -positron emission tomography ( PET ) image assessment tumor activity diagnosis , prior surgical resection . IV . To compare detectable tumor burden pre-surgical resection radioiodinated-MIBG diagnostic scan immediate post-MIBG therapy 131I-MIBG scan . V. To test relationship occurrence sinusoidal obstruction syndrome ( SOS ) Bu/Mel whole-body radiation dose delay radiation clearance due 131I-MIBG . VI . To analyze busulfan pharmacokinetics measure area curve ( AUC ) relate exposure SOS incidence . OUTLINE : INDUCTION CHEMOTHERAPY : Patients receive 5 course induction therapy . Courses 1-2 : Patients receive cyclophosphamide intravenously ( IV ) 15-30 minute topotecan hydrochloride IV 30 minute day 1-5 . Patients undergo peripheral blood stem cell ( PBSC ) collection course 2 . Course 3 5 : Patients receive cisplatin IV 1 hour day 1-4 etoposide phosphate IV 1-2 hour day 1-3 . Patients undergo surgery remove remain tumor follow course 5 . Course 4 : Patients receive cyclophosphamide IV 1-6 hour day 1-2 vincristine sulfate IV 1 minute doxorubicin hydrochloride IV 24 hour day 1-3 . Treatment repeat every 21 day total 5 course absence disease progression unacceptable toxicity . Patients without progressive disease proceed iobenguane I 131 induction therapy begin 3-6 week course 5 . Patients receive iobenguane I 131 IV 90-120 minute day 1 . SURGERY : Patients undergo surgery course 4 consolidation therapy . CONSOLIDATION THERAPY : Within 10-12 week date iobenguane I 131 infusion , patient receive busulfan IV 2 hour every 6 hour day -6 -3 melphalan IV day -1 . AUTOLOGOUS STEM CELL RESCUE : Patients undergo infusion PBSC day 0 . RADIOTHERAPY : Beginning sooner 42 day peripheral blood stem cell infusion , patient undergo 12 fraction external-beam radiotherapy ( 2 dimensional [ D ] , 3D-conformal , intensity-modulated ) area residual disease , primary tumor site , involve nodal disease . MAINTENANCE THERAPY : Beginning 66 day transplantation , patient receive isotretinoin orally ( PO ) twice daily ( BID ) day 1-14 . Treatment repeat every 28 day 6 course . After completion study therapy , patient follow every 3 month 1 year , every 6 month 4 year , annually 5 year .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Ganglioneuroblastoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>3-Iodobenzylguanidine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<criteria>Patients diagnosis neuroblastoma ( International Classification Diseases Oncology [ ICDO ] morphology 9500/3 ) ganglioneuroblastoma verify histology demonstration clump tumor cell bone marrow elevate urinary catecholamine metabolite ; patient follow disease stage diagnosis eligible , meet specified criterion : Patients newly diagnose neuroblastoma International Neuroblastoma Staging System ( INSS ) stage 4 eligible following : vMYC myelocytomatosis viral related oncogene , neuroblastoma derive ( avian ) ( MYCN ) amplification ( &gt; 4fold increase MYCN signal compare reference signal ) age &gt; = 365 day regardless additional biologic feature Age &gt; 18 month ( &gt; 547 day ) regardless biologic feature Age 1218 month ( 365547 day ) follow 3 unfavorable biologic feature ( MYCN amplification , unfavorable pathology and/or deoxyribonucleic acid [ DNA ] index = 1 ) biologic feature indeterminant/unsatisfactory/unknown Patients newly diagnose neuroblastoma INSS stage 3 eligible following : MYCN amplification ( &gt; 4fold increase MYCN signal compare reference signal ) , age &gt; = 365 day , regardless additional biologic feature Age &gt; 18 month ( &gt; 547 day ) unfavorable pathology , regardless MYCN status Patients newly diagnose INSS stage 2a/2b MYCN amplification ( &gt; 4fold increase MYCN signal compare reference signal ) age &gt; = 365 day , regardless additional biologic feature Patients &gt; = 365 day initially diagnose : INSS stage 1 , 2 , 4S progress stage 4 without interval chemotherapy ; patient must enrol ANBL00B1 ; note study enrollment must occur within 4 week progression stage 4 INSS stage 1 , 2 , 4S Patients must prior systemic therapy except localized emergency radiation sit lifethreatening functionthreatening disease and/or 1 cycle chemotherapy per low intermediaterisk neuroblastoma therapy ( P9641 , A3961 , ANBL0531 ) prior determination MYCN amplification histology Creatinine clearance radioisotope glomerular filtration rate ( GFR ) &gt; = 70 mL/min/1.73 m^2 OR serum creatinine base age and/or gender follow : 0.6 mg/dL ( 1 &lt; 2 year age ) 0.8 mg/dL ( 2 &lt; 6 year age ) 1.0 mg/dL ( 6 &lt; 10 year age ) 1.2 mg/dL ( 10 &lt; 13 year age ) 1.5 mg/dL ( male ) 1.4 mg/dL ( female ) ( 13 &lt; 16 year age ) 1.7 mg/dL ( male ) 1.4 mg/dL ( female ) ( &gt; = 16 year age ) Total bilirubin = &lt; 1.5 x upper limit normal ( ULN ) age Serum glutamic oxaloacetic transaminase ( SGOT ) ( aspartate aminotransferase [ AST ] ) serum glutamate pyruvate transaminase ( SGPT ) ( alanine aminotransferase [ ALT ] ) &lt; 10 x ULN age Shortening fraction &gt; = 27 % echocardiogram Ejection fraction &gt; = 50 % radionuclide evaluation No know contraindication peripheral blood stem cell ( PBSC ) collection ; example contraindication might weight size less collecting institution find feasible , physical condition would limit ability child undergo apheresis catheter placement ( necessary ) and/or apheresis procedure All patient and/or parent legal guardian must sign write informed consent All institutional , Food Drug Administration ( FDA ) , National Cancer Institute ( NCI ) requirement human study must meet Females childbearing potential must negative pregnancy test ; patient childbearing potential must agree use effective birth control method Female patient lactate must agree stop breastfeeding Patients 1218 month age INSS stage 4 3 favorable biologic feature ( i.e. , nonamplified MYCN , favorable pathology , DNA index &gt; 1 ) eligible Patients eligible receive local radiation include follow : 1200 centigray ( cGy ) 33 % kidney ( patient must least 1 kidney exceed dose/volume radiation list ) 1800 cGy 30 % liver and/or 900 cGy 50 % liver ; emergency local irradiation allow prior study entry , provide patient still meet eligibility criterion</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>